Trident Lifeline

What does Trident Lifeline do?

Trident Lifeline Ltd markets ethical pharmaceutical products and operates in the Pharmaceuticals & Biotechnology industry as a Micro Cap company. As of December 2024, it reported net sales of 12 Cr and a net profit of 3 Cr, with a market cap of Rs 308 Cr.

Overview:<BR>Trident Lifeline Ltd is engaged in the marketing of ethical pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History:<BR>Trident Lifeline Ltd was originally incorporated as a Private Limited Company on January 09, 2014. It converted to a Public Limited Company following a Shareholders' Resolution on June 02, 2022, and subsequently changed its name to "Trident Lifeline Limited" on June 10, 2022. The most recent quarterly results reported net sales and profit for December 2024.<BR><BR>Financial Snapshot:<BR>- Net Sales: 12 Cr (Quarterly Results - Dec 2024)<BR>- Net Profit: 3 Cr (Quarterly Results - Dec 2024)<BR>- Market Cap: Rs 308 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 31.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.24<BR>- Return on Equity: 12.21%<BR>- Price to Book: 6.24<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

Who are in the management team of Trident Lifeline?

As of March 2023, the management team of Trident Lifeline includes Hardik J Desai (Chairman & Executive Director), Mayurkumar Mansukhbhai Gajera (Whole Time Director & CFO), Shravan Harikrishna Patel (Managing Director), Maniya H Desai (Non-Executive Director), Aena Surana and Mishal Shailesh Patel (Independent Directors), and Jiteshkumar Ramchandra Varkal (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2023, the management team of Trident Lifeline includes the following individuals:<BR><BR>1. Hardik J Desai - Chairman & Executive Director<BR>2. Mayurkumar Mansukhbhai Gajera - Whole Time Director & CFO<BR>3. Shravan Harikrishna Patel - Managing Director<BR>4. Maniya H Desai - Non-Executive Director<BR>5. Aena Surana - Independent Director<BR>6. Mishal Shailesh Patel - Independent Director<BR>7. Jiteshkumar Ramchandra Varkal - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Has Trident Lifeline declared dividend?

No Dividend History Available

Who are the peers of the Trident Lifeline?

Trident Lifeline's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Gennex Lab, Sanjiv Parant, Ambalal Sarabhai, Sat Kartar, and Balaxi Pharma. Trident Lifeline has average management risk, good capital structure, and a 1-year return of 77.75%, outperforming several peers.

Peers: The peers of Trident Lifeline are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Gennex Lab., Sanjiv.Parant., Ambalal Sarabhai, Sat Kartar, and Balaxi Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Divi's Lab., and Sanjiv.Parant., while Average management risk is found at Trident Lifeline. Below Average management risk is noted for Gennex Lab., Ambalal Sarabhai, and Sat Kartar. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Trident Lifeline, and Sanjiv.Parant., while Below Average growth is seen at Divi's Lab. and Torrent Pharma. Good growth is observed at Gennex Lab., and the rest show Below Average growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Gennex Lab., while Good capital structure is noted for Torrent Pharma and Trident Lifeline. Average capital structure is found at Sanjiv.Parant., and Below Average at Ambalal Sarabhai and Sat Kartar.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while Gennex Lab. has the lowest at -23.39%. Trident Lifeline's 1-year return is 77.75%, which is higher than both. Additionally, Gennex Lab., Ambalal Sarabhai, and Sanjiv.Parant. have negative six-month returns.

What is the technical trend for Trident Lifeline?

As of June 6, 2025, Trident Lifeline's trend is mildly bullish due to a bullish MACD and Bollinger Bands, despite some mixed signals from daily moving averages and other indicators.

As of 6 June 2025, the technical trend for Trident Lifeline has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are also bullish, indicating positive momentum. However, the daily moving averages remain mildly bearish, which suggests some short-term weakness. The weekly KST is bearish, and the Dow Theory indicates a mildly bearish stance on the weekly timeframe, adding caution to the overall outlook. The RSI shows no signals on both weekly and monthly timeframes. Overall, the current stance is mildly bullish, driven primarily by the bullish MACD and Bollinger Bands, despite some mixed signals from other indicators.

Who are the top shareholders of the Trident Lifeline?

The top shareholders of Trident Lifeline include Hardik Jigishkumar Desai with 23.5%, foreign institutional investors holding 6.62%, and Nav Capital Vcc - Nav Capital Emerging Star Fund with 6.01%. Individual investors own 18.26%, while no mutual funds hold shares in the company.

The top shareholders of Trident Lifeline include the promoters, who hold the majority of the shares. The promoter with the highest holding is Hardik Jigishkumar Desai, who owns 23.5% of the company. Additionally, foreign institutional investors (FIIs) hold 6.62% of the shares through three different entities. The highest public shareholder is Nav Capital Vcc - Nav Capital Emerging Star Fund, which holds 6.01%. Individual investors collectively own 18.26% of the company. There are no mutual funds currently holding shares in Trident Lifeline.

How big is Trident Lifeline?

As of 24th July, Trident Lifeline Ltd has a market capitalization of 310.00 Cr, with Net Sales of 59.56 Cr and a Net Profit of 10.20 Cr for the latest four quarters. Shareholder's Funds are valued at 52.90 Cr, and Total Assets amount to 86.93 Cr as of March 2024.

As of 24th July, <BR><BR>Trident Lifeline Ltd has a market capitalization of 310.00 Cr, categorizing it as a Micro Cap company. <BR><BR>For the latest four quarters, the company reported Net Sales of 59.56 Cr and a Net Profit of 10.20 Cr. <BR><BR>As of March 2024, the Shareholder's Funds were valued at 52.90 Cr, while the Total Assets amounted to 86.93 Cr.

Are Trident Lifeline latest results good or bad?

Trident Lifeline's latest results show strong profitability with a 127.66% increase in Profit After Tax, but a 13.7% decline in net sales raises concerns about revenue stability. The stock is currently rated as a 'Sell' by MarketsMOJO, indicating caution for investors.

Trident Lifeline's latest results present a mixed picture. On the positive side, the company reported a Profit After Tax (PAT) of Rs 6.42 crore for the half-year, which is a remarkable year-on-year growth of 127.66%. Additionally, they achieved their highest quarterly Operating Profit (PBDIT) at Rs 4.08 crore, with an improved Operating Profit Margin of 34.49%, indicating better operational efficiency.<BR><BR>However, there are significant concerns regarding net sales, which totaled Rs 11.83 crore for the quarter, reflecting a decline of 13.7% compared to the average net sales of the previous four quarters. This drop in revenue generation is a notable challenge for the company.<BR><BR>Overall, while Trident Lifeline shows strong profitability metrics, the decrease in net sales raises potential concerns about its revenue stability. The stock is currently rated as a 'Sell' by MarketsMOJO, which suggests caution for investors.

Is Trident Lifeline overvalued or undervalued?

As of October 30, 2025, Trident Lifeline is considered very expensive with a PE ratio of 23.10 and an EV to EBIT ratio of 24.99, indicating overvaluation compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 13.93%.

As of 30 October 2025, Trident Lifeline's valuation grade has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued, with a PE ratio of 23.10, an EV to EBIT ratio of 24.99, and a Price to Book Value of 5.98. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Trident Lifeline's valuation stands out, particularly against Sun Pharma Industries, which has a PE ratio of 35.63, and Cipla, which is valued attractively at a PE of 22.87. The PEG ratio of 0.28 for Trident Lifeline further emphasizes its overvaluation, especially when compared to Divi's Lab's PEG of 2.03. Notably, Trident Lifeline has outperformed the Sensex over various periods, including a 13.93% return year-to-date, which may reflect investor optimism despite the high valuation metrics.

When is the next results date for Trident Lifeline?

The next results date for Trident Lifeline is 11 November 2025.

The next results date for Trident Lifeline is scheduled for 11 November 2025.

How has been the historical performance of Trident Lifeline?

Trident Lifeline has shown significant growth in net sales, operating income, and profitability from Mar'22 to Mar'25, with net sales increasing from 21.77 Cr to 86.96 Cr and profit after tax rising from 3.95 Cr to 10.49 Cr. However, cash flow from operations has declined, with a cash outflow of 10.00 Cr in Mar'25.

Answer:<BR>The historical performance of Trident Lifeline shows significant growth in various financial metrics over the past four years.<BR><BR>Breakdown:<BR>Trident Lifeline's net sales have increased dramatically from 21.77 Cr in Mar'22 to 86.96 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 21.77 Cr to 86.96 Cr during the same period. The company's total expenditure also grew, from 19.06 Cr in Mar'22 to 72.11 Cr in Mar'25, driven by higher raw material costs and employee expenses. Operating profit (PBDIT) saw a substantial increase, reaching 23.08 Cr in Mar'25, up from just 3.31 Cr in Mar'22. Profit before tax rose from 2.98 Cr in Mar'22 to 13.61 Cr in Mar'25, while profit after tax increased from 3.95 Cr to 10.49 Cr in the same timeframe. The earnings per share (EPS) improved significantly from 4.94 in Mar'22 to 10.22 in Mar'25. On the balance sheet, total assets grew from 12.80 Cr in Mar'22 to 153.60 Cr in Mar'25, with total liabilities also increasing from 12.80 Cr to 153.60 Cr. Cash flow from operating activities showed a negative trend, with a cash outflow of 10.00 Cr in Mar'25 compared to a positive inflow of 2.00 Cr in Mar'24. Overall, Trident Lifeline has demonstrated robust growth in sales and profitability, although cash flow from operations has been challenging in recent years.

How has been the historical performance of Trident Lifeline?

Trident Lifeline has shown significant growth over the past four years, with net sales increasing from 21.77 Cr in Mar'22 to 86.96 Cr in Mar'25, and profit after tax rising from 3.95 Cr to 10.49 Cr. However, cash flow from operating activities has been negative, indicating challenges despite overall revenue and profitability growth.

Answer:<BR>The historical performance of Trident Lifeline shows significant growth in various financial metrics over the past four years.<BR><BR>Breakdown:<BR>Trident Lifeline's net sales have increased from 21.77 Cr in Mar'22 to 86.96 Cr in Mar'25, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 21.77 Cr to 86.96 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, from 19.06 Cr in Mar'22 to 72.11 Cr in Mar'25. Operating profit (PBDIT) has improved markedly, from 3.31 Cr in Mar'22 to 23.08 Cr in Mar'25, although the operating profit margin has slightly decreased from 12.45% to 17.08%. Profit before tax has risen from 2.98 Cr to 13.61 Cr, leading to a profit after tax increase from 3.95 Cr to 10.49 Cr. The consolidated net profit has also shown growth, moving from 3.95 Cr in Mar'22 to 11.75 Cr in Mar'25. On the balance sheet, total assets have surged from 12.80 Cr to 153.60 Cr, while total liabilities have increased from 12.80 Cr to 153.60 Cr as well, indicating a proportional rise in both assets and liabilities. Cash flow from operating activities has been negative in recent years, with a cash outflow of 10.00 Cr in Mar'25, despite a positive cash flow from financing activities of 19.00 Cr. Overall, Trident Lifeline has demonstrated robust growth in revenue and profitability, alongside increasing liabilities and assets.

Should I buy, sell or hold Trident Lifeline Ltd?

Which are the latest news on Trident Lifeline?

Why is Trident Lifeline Ltd falling/rising?

As of 08-Feb, Trident Lifeline Ltd's stock price is stable at Rs 296.40, despite recent declines of 0.29% over the week and 5.00% over the month. Long-term growth remains strong, with a 20.00% increase over the past year and positive financial indicators suggesting potential for future stability and growth.

As of 08-Feb, Trident Lifeline Ltd's stock price is currently stable at Rs 296.40, showing no change (0.00%). Despite this stability, the stock has experienced a decline over the past week and month, with a decrease of 0.29% and 5.00%, respectively. However, it has outperformed the sector today by 2.21%, indicating some positive momentum.<BR><BR>The stock opened with a gain of 2.12% today and reached an intraday high of Rs 296.40, suggesting a brief period of upward movement. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 13.64% compared to the 5-day average, which may contribute to a more favorable trading environment.<BR><BR>On a longer-term basis, Trident Lifeline Ltd has shown significant growth, with a 20.00% increase over the past year and an impressive 103.01% rise over the last three years. The company's strong financial health is underscored by a low Debt to EBITDA ratio of 0.77 times and robust growth in net sales and operating profit, which have increased at annual rates of 58.70% and 55.07%, respectively. Furthermore, rising promoter confidence, as evidenced by a 1% increase in their stake, reflects a positive outlook for the company's future.<BR><BR>In summary, while the stock has faced short-term declines, the overall performance indicators and positive developments suggest a potential for stability and growth moving forward.